重组人血管内皮抑制素联合特罗凯治疗一线化疗失败的晚期非小细胞肺癌的临床疗效  

Clinical Efficacy of Recombinant Human Endostatin Combined with Tarceva in the Treatment of Advanced Non-small Cell Lung Cancer with First-line Chemotherapy Failure

作　　者：陈恩田 夏丹 CHEN Entian;XIA Dan(Bazhong Hospital,Bazhong,636000)

机构地区：[1]四川省巴中市中心医院

出　　处：《实用癌症杂志》2019年第9期1553-1556,共4页The Practical Journal of Cancer

摘　　要：目的探究重组人血管内皮抑制素联合特罗凯治疗一线化疗失败的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效。方法收集一线化疗失败的晚期NSCLC患者243例,并随机分为观察组(n=121)与对照组(n=122)。观察组给予重组人血管内皮抑制素联合特罗凯治疗,对照组给予特罗凯单药治疗。治疗3个周期后,比较2组患者的血清CEA、CA199、CA125等肿瘤标志物水平、KPS评分、治疗有效率、疾病控制率、治疗期间死亡率与不良反应发生率,同时分析重组人血管内皮抑制素联合特罗凯对不同病理类型NSCLC的治疗效果。结果与对照组相比,观察组患者的血清CEA、CA199与CA125等肿瘤标志物水平降低,KPS评分、治疗有效率及疾病控制率明显提高,而治疗期间死亡率与不良反应发生率明显降低,且差异具有统计学意义(P<0.05)。此外,重组人血管内皮抑制素联合特罗凯对鳞癌与腺癌的疗效显著(P<0.05),而对腺鳞癌的效果不明显(P>0.05)。结论在一线化疗方案失败后,给予重组人血管内皮抑制素联合特罗凯治疗晚期NSCLC的疗效显著(鳞癌与腺癌),具有一定的临床推广价值。Objective To explore the clinical efficacy of recombinant human endostatin combined with Tarceva in the treatment of advanced non-small cell lung cancer(NSCLC)with first-line chemotherapy failure.Methods 243 cases of advanced NSCLC patients who failed in the first line chemotherapy were collected and randomly divided into the observation group(n=121)and the control group(n=122).The observation group was treated with recombinant human endostatin combined with Tarceva,while the control group was given Tarceva single drug treatment.After 3 cycles of treatment,the levels of serum CEA,CA199,CA125 and other tumor markers,KPS scores,efficiency rate,disease control rate,mortality and the adverse reactions were compared in the two groups.Meanwhile,the therapeutic effect of recombinant human endostatin combined with Tarceva in different pathological types of NSCLC was analyzed.Results Compared with the control group,the levels of serum CEA,CA199 and CA125 of the patients in the observation group were decreased,and the KPS scores,the efficiency rate and the disease control rate were all increased,while the rate of mortality during the treatment and the adverse reactions were significantly lower,and the difference was statistically significant(P<0.05).In addition,recombinant human endostatin combined with Tarceva had significant effects in squamous cell carcinoma and adenocarcinoma(P<0.05),but the effect in adenosquamous carcinoma was not obvious(P>0.05).Conclusion After the failure of the first-line chemotherapy program,the therapeutic effect of recombinant human endostatin combined with Tarceva in the treatment of advanced NSCLC patients(squamous cell carcinoma and adenocarcinoma)has a certain value of clinical promotion.

关 键 词：重组人血管内皮抑制素 特罗凯 晚期非小细胞肺癌 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]